PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.

Abstract

Radiopharmaceuticals have been utilized for men with advanced prostate cancer for decades. Older agents, seldom used today, provided palliation for bone metastatic pain. In 2013, the alpha emitter radium-223 provided a catalyst for the field by prolonging survival in men with metastatic castrate-resistant prostate cancer (mCRPC). Recently radioisotopic therapies have gained further interest with the development and FDA approval of 177 lutetium (177Lu)-PSMA-617 (also known as lutetium Lu-177 vipivotide tetraxetan). This agent targets the prostate-specific membrane antigen (PSMA) expressed on the cell surface of prostate cancer cells with a beta-emitting isotope (177Lu). This clinical review summarizes key data reported from 177Lu-PSMA-617 clinical trials, including data from the phase III VISION trial which were pivotal for regulatory approval in heavily pretreated PSMA-PET-positive patients with mCRPC. The current field of radiopharmaceuticals is in a rapid state of flux. Additional phase III trials are now ongoing in patients with mCRPC and in patients with metastatic castrate-sensitive prostate cancer. The results from these potential practice-changing trials are highly anticipated. Earlier phase trials (I/II) are in progress examining combination therapies, radiolabeled monoclonal antibodies, and novel compounds. Studies of PSMA-targeted therapies using both beta emitters such as 177Lu and novel alpha emitters such 225 actinium are in progress. During the next decade, radiopharmaceuticals will likely play a central role in the management of patients with advanced prostate cancer.

• Authors: Brian Ramnaraign, Oliver Sartor
• Journal: The oncologist (Oncologist) Vol. 28 Issue 5 Pg. 392-401 (05 08 2023) ISSN: 1549-490X [Electronic] England
• PMID: 36806966 (Publication Type: Journal Article)
• Copyright: © The Author(s) 2023. Published by Oxford University Press.

Chemical References

• Radiopharmaceuticals
• Lutetium-177
• Lutetium
• Dipeptides
• Prostate-Specific Antigen

Topics

• Male
• Humans
• Radiopharmaceuticals (therapeutic use)
• Lutetium (therapeutic use)
• Prostatic Neoplasms, Castration-Resistant (drug therapy, radiotherapy)
• Treatment Outcome
• Dipeptides (adverse effects)
• Prostate-Specific Antigen